THE MEDICINES COMPANY SHAREHOLDERS NOTICE: Shareholder Rights Law Firm
Johnson & Weaver, LLP Announces Investigation of Certain Officers and
Directors of The Medicines Company
SAN DIEGO -- February 13, 2014
Shareholder Rights Law Firm Johnson & Weaver, LLP today announced that it is
investigating whether the board of directors of The Medicines Company
(NASDAQ:MDCO) breached its fiduciary duties to shareholders related to its
management, communication and planning regarding cangrelor in light of an FDA
On February 10, 2014 an investigator for the FDA wrote about cangrelor, a drug
being developed by The Medicines Company. In the report, the investigator
indicated that cangrelor should not be approved for patients who are
undergoing an angioplasty, a procedure that is used to open narrowed or
blocked coronary arteries. Additionally, the FDA investigator reported that
the drug does not appear to work better than an older drug currently on the
market. Finally, the report was concerned about the methods that were used in
the study criticizing those methods as being unethical. The FDA reviewer noted
that cangrelor should not be approved on that fact alone.
Since this news was announced, The Medicines Company’s shares have fallen more
than 15% as of February 13, 2014 in mid-day trading. Our investigation
concerns whether the Company’s board of directors has breached its fiduciary
duties to shareholders in connection with the foregoing.
If you are a shareholder of The Medicines Company and would like additional
information concerning your legal rights, please contact lead analyst Jim
Baker (email@example.com) at (619) 230-0063.
Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law
firm. The firm represents individual and institutional investors in
shareholder derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please
Johnson & Weaver, LLP
Jim Baker, 619-230-0063 Ext 118
Press spacebar to pause and continue. Press esc to stop.